Acadia Pharmaceuticals | ACAD - Equity Capital And Reserves

Stock Price
21.40
Daily Change
-0.69 -3.12%
Monthly
0.71%
Yearly
-3.86%
Q2 Forecast
20.97

Acadia Pharmaceuticals reported $1.25B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
ALKERMES USD 1.75B 67.76M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Cara Therapeutics USD 20.95M 6.92M Dec/2025
Corcept Therapeutics USD 637.99M 9.82M Mar/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
Eisai JPY 889.64B 35.21B Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
J&J USD 81.19B 358M Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Prothena USD 312.62M 32.14M Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026